[{"address1": "1500 Broadway", "address2": "Suite 1401", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "332 208 6102", "website": "https://www.nuvationbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.", "fullTimeEmployees": 159, "auditRisk": 8, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 3.03, "open": 3.04, "dayLow": 2.965, "dayHigh": 3.07, "regularMarketPreviousClose": 3.03, "regularMarketOpen": 3.04, "regularMarketDayLow": 2.965, "regularMarketDayHigh": 3.07, "beta": 1.418, "forwardPE": -7.093023, "volume": 3327973, "regularMarketVolume": 3327973, "averageVolume": 1712658, "averageVolume10days": 1425430, "averageDailyVolume10Day": 1425430, "bidSize": 2900, "askSize": 3100, "marketCap": 756921536, "fiftyTwoWeekLow": 0.95, "fiftyTwoWeekHigh": 4.16, "fiftyDayAverage": 3.0038, "twoHundredDayAverage": 2.00457, "currency": "USD", "enterpriseValue": 160426480, "floatShares": 147251914, "sharesOutstanding": 247171008, "sharesShort": 3314464, "sharesShortPriorMonth": 3192248, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0134000005, "heldPercentInsiders": 0.2721, "heldPercentInstitutions": 0.52871, "shortRatio": 2.74, "shortPercentOfFloat": 0.0217, "impliedSharesOutstanding": 248171008, "bookValue": 2.711, "priceToBook": 1.1250461, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -68868000, "trailingEps": -0.32, "forwardEps": -0.43, "enterpriseToEbitda": -1.72, "52WeekChange": 0.75287354, "SandP52WeekChange": 0.26238096, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "NUVB", "underlyingSymbol": "NUVB", "shortName": "Nuvation Bio Inc.", "longName": "Nuvation Bio Inc.", "firstTradeDateEpochUtc": 1598448600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "292fc361-56ab-3994-b08a-1a4c45c2f81b", "messageBoardId": "finmb_639036735", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.05, "targetHighPrice": 10.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.6, "targetMedianPrice": 5.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 596976000, "totalCashPerShare": 2.415, "ebitda": -93276000, "totalDebt": 3532000, "quickRatio": 38.146, "currentRatio": 38.577, "debtToEquity": 0.595, "returnOnAssets": -0.09201, "returnOnEquity": -0.11152001, "freeCashflow": -41272500, "operatingCashflow": -64371000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]